SITAXSENTAN IMPROVES TIME TO CLINICAL WORSENING IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION

CHEST Journal ◽  
2005 ◽  
Vol 128 (4) ◽  
pp. 160S ◽  
Author(s):  
David Badesch ◽  
Nazzareno Galie ◽  
David Langleben ◽  
Robert Naeije ◽  
Gerald Simonneau ◽  
...  
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Pulmonary Arterial ◽  
Clinical Worsening

scholarly journals Assessment of the REPLACE study composite endpoint in riociguat-treated patients in the PATENT study

2020 ◽  
Vol 10 (4) ◽  
pp. 204589402097312
Author(s):  
Gérald Simonneau ◽  
Hossein-Ardeschir Ghofrani ◽  
Paul A. Corris ◽  
Stephan Rosenkranz ◽  
Ekkehard Grünig ◽  
...  
Keyword(s):  
Relative Risk ◽  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Clinical Improvement ◽  
Composite Endpoint ◽  
World Health ◽  
Walking Distance ◽  
Pulmonary Arterial ◽  
Clinical Worsening

The goal of treatment in patients with pulmonary arterial hypertension is to achieve a low risk status, indicating a favorable long-term outcome. The REPLACE study investigated the efficacy of switching to riociguat in patients with pulmonary arterial hypertension and an insufficient response to phosphodiesterase-5 inhibitors. In this post hoc analysis, we applied the REPLACE composite endpoint of clinical improvement to the placebo-controlled PATENT-1 study of riociguat in pulmonary arterial hypertension and its long-term extension, PATENT-2. Clinical improvement was defined as ≥2 of the following in patients who completed the study without clinical worsening: ≥10% or ≥30 m improvement in 6-minute walking distance; World Health Organization functional class I or II; ≥30% decrease in N-terminal prohormone of brain natriuretic peptide. At PATENT-1 Week 12, patients treated with riociguat were more likely to achieve the composite endpoint vs. placebo ( P < 0.0001), with similar results in pretreated ( P = 0.0189) and treatment-naïve ( P < 0.0001) patients. Achievement of the composite endpoint at Week 12 was associated with a 45% reduction in relative risk of death and a 19% reduction in relative risk of clinical worsening in PATENT-2. Overall, these data suggest that use of the REPLACE composite endpoint in patients with pulmonary arterial hypertension is a valid assessment of response to treatment.

scholarly journals Association between MDR1 gene polymorphism and clinical course of pediatric pulmonary arterial hypertension

2018 ◽  
Vol 26 (3) ◽  
pp. 305-312
Author(s):  
Iolanda Muntean ◽  
Carmen Şuteu ◽  
Rodica Togănel ◽  
Claudia Bănescu
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Progressive Disease ◽  
Pediatric Patients ◽  
Clinical Course ◽  
Heart Defects ◽  
Mdr1 Gene ◽  
Pulmonary Arterial ◽  
Mdr1 Polymorphism ◽  
Clinical Worsening

Abstract Pulmonary arterial hypertension (PAH) is a progressive disease with a complex pathogenesis. The polymorphism of the gene of multidrug resistance-1 (MDR1) has been associated with many diseases including PAH. Objective. In this study we aimed to investigate the relevance of the MDR1 polymorphism to pediatric PAH clinical course. Methods. A total of 40 pediatric patients with PAH (secondary to congenital heart defects or idiopathic) and 40 control subjects were enrolled. Patients with PAH were divided into 2 groups, according to their evolution: 28 patients who remained clinically stable at 12-months (non-worsening group) and 12 patients who presented clinical worsening at 12-months (worsening group). Genomic DNA was genotyped for MDR1 gene polymorphisms as follows: C1236T, G2677T and C3435T. Results. There were no significant differences between PAH children groups (clinical worsening and non-worsening) nor between PAH children and controls in terms of frequency distribution of the three studied genotypes or alleles. Conclusions. The MDR1 polymorphism could not be correlated with the clinical evolution of pediatric PAH patients in our study.

scholarly journals Cardiac-MRI Predicts Clinical Worsening and Mortality in Pulmonary Arterial Hypertension

2020 ◽  
Author(s):  
Samer Alabed ◽  
Yousef Shahin ◽  
Pankaj Garg ◽  
Faisal Alandejani ◽  
Christopher S. Johns ◽  
...  
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Cardiac Mri ◽  
Pulmonary Arterial ◽  
Clinical Worsening

Right ventricular concentric hypertrophy and clinical worsening in idiopathic pulmonary arterial hypertension

2016 ◽  
Vol 35 (11) ◽  
pp. 1321-1329 ◽  
Author(s):  
Roberto Badagliacca ◽  
Roberto Poscia ◽  
Beatrice Pezzuto ◽  
Silvia Papa ◽  
Francesca Pesce ◽  
...  
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Right Ventricular ◽  
Idiopathic Pulmonary Arterial Hypertension ◽  
Concentric Hypertrophy ◽  
Pulmonary Arterial ◽  
Clinical Worsening

scholarly journals Plasma Soluble ST2 Levels Correlate With Disease Severity and Predict Clinical Worsening in Patients With Pulmonary Arterial Hypertension

2014 ◽  
Vol 37 (6) ◽  
pp. 365-370 ◽  
Author(s):  
Ya-Guo Zheng ◽  
Tao Yang ◽  
Jian-Guo He ◽  
Guo Chen ◽  
Zhi-Hong Liu ◽  
...  
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Disease Severity ◽  
Soluble St2 ◽  
Pulmonary Arterial ◽  
Clinical Worsening
Sign in / Sign up

Export Citation Format

Share Document